Fig. 5: Combining complementary biomarkers to predict lung cancer.
From: Circulating T-cell receptor repertoire for cancer early detection
(a) Cross-validated ROC curve of SVM model score using the protein expression features only. (b) Circulating DNA mutation counts in the assayed subjects by cancer stage. (c) Cross-validated ROC curve of prediction score from logistic regression with forward feature selection using the mutation features only. Cancer detection sensitivity using different subset of analytes for stage I and stage II-IV lung cancer is shown in (d) and (e), respectively.
